Human conditions of insulin-like growth factor-I (IGF-I) deficiency

Journal of Translational Medicine

Inma Castilla-Cortázar¹  Juan E Puche¹ 

[1] Applied Molecular Medicine Institute (IMMA), School of Medicine, Department of Medical Physiology, Universidad CEU San Pablo, Madrid, Spain

关键词: Cancer protection;    Growth;    Cellular protection;    Mitochondrial dysfunction;    GH/IGF-I axis;    Oxidative stress;    Aging;    Liver cirrhosis;    Laron syndrome;   

Others  :  1205894
DOI  :  10.1186/1479-5876-10-224

 received in 2012-07-11, accepted in 2012-11-07,  发布年份 2012

【 摘 要 】

Insulin-like growth factor I (IGF-I) is a polypeptide hormone produced mainly by the liver in response to the endocrine GH stimulus, but it is also secreted by multiple tissues for autocrine/paracrine purposes. IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).

IGF-I is a closely regulated hormone. Consequently, its logical therapeutical applications seems to be limited to restore physiological circulating levels in order to recover the clinical consequences of IGF-I deficiency, conditions where, despite continuous discrepancies, IGF-I treatment has never been related to oncogenesis. Currently the best characterized conditions of IGF-I deficiency are Laron Syndrome, in children; liver cirrhosis, in adults; aging including age-related-cardiovascular and neurological diseases; and more recently, intrauterine growth restriction.

The aim of this review is to summarize the increasing list of roles of IGF-I, both in physiological and pathological conditions, underlying that its potential therapeutical options seem to be limited to those proven states of local or systemic IGF-I deficiency as a replacement treatment, rather than increasing its level upper the normal range.

【 授权许可】

   
2012 Puche and Castilla-Cortazar; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Le Roith D: Seminars in medicine of the beth israel deaconess medical center. Insulin-like growth factors. N Engl J Med 1997, 336(9):633-640.
• [2]Salmon WD Jr, Daughaday WH: A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957, 49(6):825-836.
• [3]Froesch ER, Buergi H, Ramseier EB, Bally P, Labhart A: Antibody-suppressible and nonsuppressible insulin-like activities in human serum and their physiologic significance. An insulin assay with adipose tissue of increased precision and specificity. J Clin Invest 1963, 42:1816-1834.
• [4]Pierson RW Jr, Temin HM: The partial purification from calf serum of a fraction with multiplication-stimulating activity for chicken fibroblasts in cell culture and with non-suppressible insulin-like activity. J Cell Physiol 1972, 79(3):319-330.
• [5]Daughaday WH, Hall K, Raben MS, Salmon WD Jr, van den Brande JL, van Wyk JJ: Somatomedin: proposed designation for sulphation factor. Nature 1972, 235(5333):107.
• [6]Rinderknecht E, Humbel RE: The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978, 253(8):2769-2776.
• [7]Rinderknecht E, Humbel RE: Primary structure of human insulin-like growth factor II. FEBS Lett 1978, 89(2):283-286.
• [8]Klapper DG, Svoboda ME, Van Wyk JJ: Sequence analysis of somatomedin-C: confirmation of identity with insulin-like growth factor I. Endocrinology 1983, 112(6):2215-2217.
• [9]Zapf J, Schoenle E, Froesch ER: Insulin-like growth factors I and II: some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulin-like activity of human serum. European journal of biochemistry / FEBS 1978, 87(2):285-296.
• [10]Froesch ER, Zapf J, Audhya TK, Ben-Porath E, Segen BJ, Gibson KD: Nonsuppressible insulin-like activity and thyroid hormones: major pituitary-dependent sulfation factors for chick embryo cartilage. Proc Natl Acad Sci U S A 1976, 73(8):2904-2908.
• [11]Rinderknecht E, Humbel RE: Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: isolation, chemical characterization, and some biological properties of forms I and II. Proc Natl Acad Sci U S A 1976, 73(7):2365-2369.
• [12]Daughaday WH, Hall K, Salmon WD Jr, Van den Brande JL, Van Wyk JJ: On the nomenclature of the somatomedins and insulin-like growth factors. J Clin Endocrinol Metab 1987, 65(5):1075-1076.
• [13]Clemmons DR: Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998, 140(1–2):19-24.
• [14]Clemmons DR, Busby W, Clarke JB, Parker A, Duan C, Nam TJ: Modifications of insulin-like growth factor binding proteins and their role in controlling IGF actions. Endocr J 1998, 45(Suppl):S1-S8.
• [15]Annenkov A: The insulin-like growth factor (IGF) receptor type 1 (IGF1R) as an essential component of the signalling network regulating neurogenesis. Mol Neurobiol 2009, 40(3):195-215.
• [16]Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM: The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008, 14(20):6364-6370.
• [17]LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995, 16(2):143-163.
• [18]D’Ercole AJ, Applewhite GT, Underwood LE: Evidence that somatomedin is synthesized by multiple tissues in the fetus. Dev Biol 1980, 75(2):315-328.
• [19]Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Pollock BH: Growth in growth hormone insensitivity. Trends in endocrinology and metabolism: TEM 1994, 5(7):296-303.
• [20]Ghigo MC, Torsello A, Grilli R, Luoni M, Guidi M, Cella SG, Locatelli V, Muller EE: Effects of GH and IGF-I administration on GHRH and somatostatin mRNA levels: I. A study on ad libitum fed and starved adult male rats. J Endocrinol Invest 1997, 20(3):144-150.
• [21]Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L, Hintz RL: Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science 1981, 212(4500):1279-1281.
• [22]Bertherat J, Bluet-Pajot MT, Epelbaum J: Neuroendocrine regulation of growth hormone. Eur J Endocrinol 1995, 132(1):12-24.
• [23]Ohlsson C, Mohan S, Sjogren K, Tivesten A, Isgaard J, Isaksson O, Jansson JO, Svensson J: The role of liver-derived insulin-like growth factor-I. Endocr Rev 2009, 30(5):494-535.
• [24]Daughaday WH, Rotwein P: Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989, 10(1):68-91.
• [25]Clemmons DR, Underwood LE: Nutritional regulation of IGF-I and IGF binding proteins. Annu Rev Nutr 1991, 11:393-412.
• [26]Murphy LJ, Friesen HG: Differential effects of estrogen and growth hormone on uterine and hepatic insulin-like growth factor I gene expression in the ovariectomized hypophysectomized rat. Endocrinology 1988, 122(1):325-332.
• [27]Adashi EY, Resnick CE, Hurwitz A, Ricciarelli E, Hernandez ER, Roberts CT, Leroith D, Rosenfeld R: Insulin-like growth factors: the ovarian connection. Hum Reprod 1991, 6(9):1213-1219.
• [28]Cohick WS, Clemmons DR: The insulin-like growth factors. Annu Rev Physiol 1993, 55:131-153.
• [29]Adamo M, Lowe WL Jr, LeRoith D, Roberts CT Jr: Insulin-like growth factor I messenger ribonucleic acids with alternative 5’-untranslated regions are differentially expressed during development of the rat. Endocrinology 1989, 124(6):2737-2744.
• [30]Wolf E, Hoeflich A, Lahm H: What is the function of IGF-II in postnatal life? Answers from transgenic mouse models. Growth Horm IGF Res 1998, 8(3):185-193.
• [31]Zhou Y, Xu BC, Maheshwari HG, He L, Reed M, Lozykowski M, Okada S, Cataldo L, Coschigamo K, Wagner TE, et al.: A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci U S A 1997, 94(24):13215-13220.
• [32]Wit JM, van Unen H: Growth of infants with neonatal growth hormone deficiency. Arch Dis Child 1992, 67(7):920-924.
• [33]Savage MO, Blum WF, Ranke MB, Postel-Vinay MC, Cotterill AM, Hall K, Chatelain PG, Preece MA, Rosenfeld RG: Clinical features and endocrine status in patients with growth hormone insensitivity (laron syndrome). J Clin Endocrinol Metab 1993, 77(6):1465-1471.
• [34]Laron Z: Laron syndrome—primary growth hormone resistance. In Hormone resistance syndromes contemporary endocrinology. Edited by Jameson JL. Humana Press, NJ; 1999:17-37. vol. 2
• [35]Savage MO, Burren CP, Blair JC, Woods KA, Metherell L, Clark AJ, Camacho-Hubner C: Growth hormone insensitivity: pathophysiology, diagnosis, clinical variation and future perspectives. Horm Res 2001, 55(Suppl 2):32-35.
• [36]Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A: Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001, 229(1):141-162.
• [37]Baker J, Liu JP, Robertson EJ, Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993, 75(1):73-82.
• [38]Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993, 75(1):59-72.
• [39]Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, Kiess W, Klammt J, Kratzsch J, Osgood D, et al.: IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Eng J Med 2003, 349(23):2211-2222.
• [40]Woods KA, Camacho-Hubner C, Savage MO, Clark AJ: Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Eng J Med 1996, 335(18):1363-1367.
• [41]Leal Ade C, Canton AP, Montenegro LR, Coutinho DC, Arnhold IJ, Jorge AA: Mutations in insulin-like growth factor receptor 1 gene (IGF1R) resulting in intrauterine and postnatal growth retardation. Arq Bras Endocrinol Metabol 2011, 55(8):541-549.
• [42]Daughaday WH: Growth hormone and the somatomedins. In Endocrine control of growth. Edited by Daughaday WH. Elsevier, New York; 1981:1-24.
• [43]Savage MO, Attie KM, David A, Metherell LA, Clark AJ, Camacho-Hubner C: Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders. Nat Clin Pract Endocrinol Metab 2006, 2(7):395-407.
• [44]Backeljauw PF, Underwood LE, syndrome GCGGhi: Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 2001, 86(4):1504-1510.
• [45]D’Ercole AJ, Stiles AD, Underwood LE: Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci U S A 1984, 81(3):935-939.
• [46]Froesch ER, Schmid C, Schwander J, Zapf J: Actions of insulin-like growth factors. Annu Rev Physiol 1985, 47:443-467.
• [47]Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tornell J, Isaksson OG, Jansson JO, et al.: Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A 1999, 96(12):7088-7092.
• [48]Yakar S, Rosen CJ, Bouxsein ML, Sun H, Mejia W, Kawashima Y, Wu Y, Emerton K, Williams V, Jepsen K, et al.: Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J 2009, 23(3):709-719.
• [49]Chin E, Zhou J, Dai J, Baxter RC, Bondy CA: Cellular localization and regulation of gene expression for components of the insulin-like growth factor ternary binding protein complex. Endocrinology 1994, 134(6):2498-2504.
• [50]Jaques G, Noll K, Wegmann B, Witten S, Kogan E, Radulescu RT, Havemann K: Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology 1997, 138(4):1767-1770.
• [51]Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC: Nuclear import of insulin-like growth factor-binding protein-3 and −5 is mediated by the importin beta subunit. J Biol Chem 2000, 275(31):23462-23470.
• [52]Lee KW, Ma L, Yan X, Liu B, Zhang XK, Cohen P: Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77. J Biol Chem 2005, 280(17):16942-16948.
• [53]Kenner KA, Heidenreich KA: Insulin and insulin-like growth factors stimulate in vivo receptor autophosphorylation and tyrosine phosphorylation of a 70K substrate in cultured fetal chick neurons. Endocrinology 1991, 129(1):301-311.
• [54]Begum N, Robinson LJ, Draznin B, Heidenreich KA: Protein phosphatase-1 and -2a activities in cultured fetal chick neurons: differential regulation by insulin and insulin-like growth factor-I. Endocrinology 1993, 133(5):2085-2090.
• [55]Garcia-Fernandez M, Delgado G, Puche JE, Gonzalez-Baron S, Castilla Cortazar I: Low doses of insulin-like growth factor I improve insulin resistance, lipid metabolism, and oxidative damage in aging rats. Endocrinology 2008, 149(5):2433-2442.
• [56]Puche JE, Garcia-Fernandez M, Muntane J, Rioja J, Gonzalez-Baron S, Castilla Cortazar I: Low doses of insulin-like growth factor-I induce mitochondrial protection in aging rats. Endocrinology 2008, 149(5):2620-2627.
• [57]Garcia-Fernandez M, Sierra I, Puche JE, Guerra L, Castilla-Cortazar I: Liver mitochondrial dysfunction is reverted by insulin-like growth factor II (IGF-II) in aging rats. J Transl Med 2011, 9:123. BioMed Central Full Text
• [58]Castilla-Cortazar I, Garcia-Fernandez M, Delgado G, Puche JE, Sierra I, Barhoum R, Gonzalez-Baron S: Hepatoprotection and neuroprotection induced by low doses of IGF-II in aging rats. J Transl Med 2011, 9:103. BioMed Central Full Text
• [59]Joseph D’Ercole A, Ye P: Expanding the mind: insulin-like growth factor I and brain development. Endocrinology 2008, 149(12):5958-5962.
• [60]Drago J, Murphy M, Carroll SM, Harvey RP, Bartlett PF: Fibroblast growth factor-mediated proliferation of central nervous system precursors depends on endogenous production of insulin-like growth factor I. Proc Natl Acad Sci U S A 1991, 88(6):2199-2203.
• [61]Popken GJ, Dechert-Zeger M, Ye P, D’Ercole AJ: Brain development. Adv Exp Med Biol 2005, 567:187-220.
• [62]Brooker GJ, Kalloniatis M, Russo VC, Murphy M, Werther GA, Bartlett PF: Endogenous IGF-1 regulates the neuronal differentiation of adult stem cells. J Neurosci Res 2000, 59(3):332-341.
• [63]Hsieh J, Aimone JB, Kaspar BK, Kuwabara T, Nakashima K, Gage FH: IGF-I instructs multipotent adult neural progenitor cells to become oligodendrocytes. J Cell Biol 2004, 164(1):111-122.
• [64]Reinhardt RR, Bondy CA: Insulin-like growth factors cross the blood–brain barrier. Endocrinology 1994, 135(5):1753-1761.
• [65]Rosenfeld RG, Pham H, Keller BT, Borchardt RT, Pardridge WM: Demonstration and structural comparison of receptors for insulin-like growth factor-I and -II (IGF-I and -II) in brain and blood–brain barrier. Biochem Biophys Res Commun 1987, 149(1):159-166.
• [66]Duffy KR, Pardridge WM, Rosenfeld RG: Human blood–brain barrier insulin-like growth factor receptor. Metab Clin Exp 1988, 37(2):136-140.
• [67]Nishijima T, Piriz J, Duflot S, Fernandez AM, Gaitan G, Gomez-Pinedo U, Verdugo JM, Leroy F, Soya H, Nunez A, et al.: Neuronal activity drives localized blood–brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron 2010, 67(5):834-846.
• [68]Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I: Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 2002, 8(12):1390-1397.
• [69]Backstrom M, Hall K, Sara V: Somatomedin levels in cerebrospinal fluid from adults with pituitary disorders. Acta Endocrinol 1984, 107(2):171-178.
• [70]Hynes MA, Van Wyk JJ, Brooks PJ, D’Ercole AJ, Jansen M, Lund PK: Growth hormone dependence of somatomedin-C/insulin-like growth factor-I and insulin-like growth factor-II messenger ribonucleic acids. Mol Endocrinol 1987, 1(3):233-242.
• [71]Chernausek SD: Insulin-like growth factor-I (IGF-I) production by astroglial cells: regulation and importance for epidermal growth factor-induced cell replication. J Neurosci Res 1993, 34(2):189-197.
• [72]Pons S, Torres-Aleman I: Basic fibroblast growth factor modulates insulin-like growth factor-I, its receptor, and its binding proteins in hypothalamic cell cultures. Endocrinology 1992, 131(5):2271-2278.
• [73]Lowe WL Jr, Adamo M, Werner H, Roberts CT Jr, LeRoith D: Regulation by fasting of rat insulin-like growth factor I and its receptor. Effects on gene expression and binding. J Clin Invest 1989, 84(2):619-626.
• [74]Hall KS, Lien B, Paulsen JE, Clausen OP, Bergan A, Rugstad HE: Effect of preoperative 4’-epidoxorubicin (epi-adriamycin) treatment on the regeneration and function of the liver in partially hepatectomized rats. European surgical research Europaische chirurgische Forschung Recherches chirurgicales europeennes 1989, 21(3–4):196-204.
• [75]Lee WH, Clemens JA, Bondy CA: Insulin-like growth factors in the response to cerebral ischemia. Mol Cell Neurosci 1992, 3(1):36-43.
• [76]Garcia-Estrada J, Garcia-Segura LM, Torres-Aleman I: Expression of insulin-like growth factor I by astrocytes in response to injury. Brain Res 1992, 592(1–2):343-347.
• [77]Yamaguchi F, Itano T, Miyamoto O, Janjua NA, Ohmoto T, Hosokawa K, Hatase O: Increase of extracellular insulin-like growth factor I (IGF-I) concentration following electrolytical lesion in rat hippocampus. Neurosci Lett 1991, 128(2):273-276.
• [78]Yao DL, West NR, Bondy CA, Brenner M, Hudson LD, Zhou J, Collins GH, Webster HD: Cryogenic spinal cord injury induces astrocytic gene expression of insulin-like growth factor I and insulin-like growth factor binding protein 2 during myelin regeneration. J Neurosci Res 1995, 40(5):647-659.
• [79]Komoly S, Hudson LD, Webster HD, Bondy CA: Insulin-like growth factor I gene expression is induced in astrocytes during experimental demyelination. Proc Natl Acad Sci U S A 1992, 89(5):1894-1898.
• [80]Yao DL, Liu X, Hudson LD, Webster HD: Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 1995, 92(13):6190-6194.
• [81]Liu X, Yao DL, Webster H: Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis. Mult Scler 1995, 1(1):2-9.
• [82]D’Ercole AJ, Ye P, Calikoglu AS, Gutierrez-Ospina G: The role of the insulin-like growth factors in the central nervous system. Mol Neurobiol 1996, 13(3):227-255.
• [83]Behringer RR, Lewin TM, Quaife CJ, Palmiter RD, Brinster RL, D’Ercole AJ: Expression of insulin-like growth factor I stimulates normal somatic growth in growth hormone-deficient transgenic mice. Endocrinology 1990, 127(3):1033-1040.
• [84]Carson MJ, Behringer RR, Brinster RL, McMorris FA: Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron 1993, 10(4):729-740.
• [85]Beck KD, Powell-Braxton L, Widmer HR, Valverde J, Hefti F: Igf1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron 1995, 14(4):717-730.
• [86]Ye P, Li L, Richards RG, DiAugustine RP, D’Ercole AJ: Myelination is altered in insulin-like growth factor-I null mutant mice. J Neurosci 2002, 22(14):6041-6051.
• [87]Skrtic S, Wallenius V, Ekberg S, Brenzel A, Gressner AM, Jansson JO: Insulin-like growth factors stimulate expression of hepatocyte growth factor but not transforming growth factor beta1 in cultured hepatic stellate cells. Endocrinology 1997, 138(11):4683-4689.
• [88]Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, Sinha MK: Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 1988, 81(4):976-981.
• [89]Skrtic S, Waññenius V, Ekberg S, Brenzel A, Gressner AJOJ: Expression pattern of growth hormone/insulin-like growth factor associated genes in rat liver. In Cells of the hepatic sinusoid. Edited by Wisse E, Knook D, Balabaud C. The Kupffer Foundation, The Netherlands; 1997:131-133.
• [90]Brenzel A, Gressner AM: Characterization of insulin-like growth factor (IGF)-I-receptor binding sites during in vitro transformation of rat hepatic stellate cells to myofibroblasts. Eur J Clin Chem Clin: J Forum Eur Clin Chem Soc 1996, 34(5):401-409.
• [91]Pinzani M, Abboud HE, Aron DC: Secretion of insulin-like growth factor-I and binding proteins by rat liver fat-storing cells: regulatory role of platelet-derived growth factor. Endocrinology 1990, 127(5):2343-2349.
• [92]Gressner AM, Brenzel A, Vossmeyer T: Hepatocyte-conditioned medium potentiates insulin-like growth factor (IGF) 1 and 2 stimulated DNA synthesis of cultured fat storing cells. Liver 1993, 13(2):86-94.
• [93]Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D: Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 1999, 96(13):7324-7329.
• [94]Sjogren K, Bohlooly YM, Olsson B, Coschigano K, Tornell J, Mohan S, Isaksson OG, Baumann G, Kopchick J, Ohlsson C: Disproportional skeletal growth and markedly decreased bone mineral content in growth hormone receptor −/− mice. Biochem Biophys Res Commun 2000, 267(2):603-608.
• [95]Shea BT, Hammer RE, Brinster RL: Growth allometry of the organs in giant transgenic mice. Endocrinology 1987, 121(6):1924-1930.
• [96]Quaife CJ, Mathews LS, Pinkert CA, Hammer RE, Brinster RL, Palmiter RD: Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology 1989, 124(1):40-48.
• [97]Pennisi PA, Kopchick JJ, Thorgeirsson S, LeRoith D, Yakar S: Role of growth hormone (GH) in liver regeneration. Endocrinology 2004, 145(10):4748-4755.
• [98]Desbois-Mouthon C, Wendum D, Cadoret A, Rey C, Leneuve P, Blaise A, Housset C, Tronche F, Le Bouc Y, Holzenberger M: Hepatocyte proliferation during liver regeneration is impaired in mice with liver-specific IGF-1R knockout. FASEB J 2006, 20(6):773-775.
• [99]Fausto N, Laird AD, Webber EM: Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J 1995, 9(15):1527-1536.
• [100]Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R: Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996, 274(5291):1379-1383.
• [101]Silva JR, Figueiredo JR, van den Hurk R: Involvement of growth hormone (GH) and insulin-like growth factor (IGF) system in ovarian folliculogenesis. Theriogenology 2009, 71(8):1193-1208.
• [102]Adashi EY: The IGF family and folliculogenesis. J Reprod Immunol 1998, 39(1–2):13-19.
• [103]Zhao J, Taverne MA, Van Der Weijden GC, Bevers MM, Van Den Hurk R: Insulin-like growth factor-I (IGF-I) stimulates the development of cultured rat pre-antral follicles. Mol Reprod Dev 2001, 58(3):287-296.
• [104]Zhao J, Taverne MA, van der Weijden GC, Bevers MM, van den Hurk R: Immunohistochemical localisation of growth hormone (GH), GH receptor (GHR), insulin-like growth factor I (IGF-I) and type I IGF-I receptor, and gene expression of GH and GHR in rat pre-antral follicles. Zygote 2002, 10(1):85-94.
• [105]Demeestere I, Gervy C, Centner J, Devreker F, Englert Y, Delbaere A: Effect of insulin-like growth factor-I during preantral follicular culture on steroidogenesis, in vitro oocyte maturation, and embryo development in mice. Biol Reprod 2004, 70(6):1664-1669.
• [106]Zhou J, Kumar TR, Matzuk MM, Bondy C: Insulin-like growth factor I regulates gonadotropin responsiveness in the murine ovary. Mol Endocrinol 1997, 11(13):1924-1933.
• [107]Monget P, Fabre S, Mulsant P, Lecerf F, Elsen JM, Mazerbourg S, Pisselet C, Monniaux D: Regulation of ovarian folliculogenesis by IGF and BMP system in domestic animals. Domest Anim Endocrinol 2002, 23(1–2):139-154.
• [108]Giudice LC: Insulin-like growth factors and ovarian follicular development. Endocr Rev 1992, 13(4):641-669.
• [109]Magoffin DA, Weitsman SR: Insulin-like growth factor-I regulation of luteinizing hormone (LH) receptor messenger ribonucleic acid expression and LH-stimulated signal transduction in rat ovarian theca-interstitial cells. Biol Reprod 1994, 51(4):766-775.
• [110]Tsuchiya M, Minegishi T, Kishi H, Tano M, Kameda T, Hirakawa T, Ibuki Y, Mizutani T, Miyamoto K: Control of the expression of luteinizing hormone receptor by local factors in rat granulosa cells. Arch Biochem Biophys 1999, 367(2):185-192.
• [111]Yu Y, Yan J, Li M, Yan L, Zhao Y, Lian Y, Li R, Liu P, Qiao J: Effects of combined epidermal growth factor, brain-derived neurotrophic factor and insulin-like growth factor-1 on human oocyte maturation and early fertilized and cloned embryo development. Hum Reprod 2012, 27(7):2146-2159.
• [112]Stanek MB, Borman SM, Molskness TA, Larson JM, Stouffer RL, Patton PE: Insulin and insulin-like growth factor stimulation of vascular endothelial growth factor production by luteinized granulosa cells: comparison between polycystic ovarian syndrome (PCOS) and non-PCOS women. J Clin Endocrinol Metab 2007, 92(7):2726-2733.
• [113]Hall P: Testicular steroid synthesis: organization and regulation. In The physiology of reproduction. Edited by Knobil E, Neill J. Raven Press, New York; 1994:1335-1362. vol. 1
• [114]Rouiller-Fabre V, Lecref L, Gautier C, Saez JM, Habert R: Expression and effect of insulin-like growth factor I on rat fetal Leydig cell function and differentiation. Endocrinology 1998, 139(6):2926-2934.
• [115]Saez J, Lejeune H: Regulation of Leydig cell function by hormones and growth factors other than LH and IGF-I. In The leydig cell. Edited by Payne A, Hardy M, Russell L. Cache River Press, Vienna; 1996:383-406. vol. 1
• [116]Vannelli BG, Barni T, Orlando C, Natali A, Serio M, Balboni GC: Insulin-like growth factor-I (IGF-I) and IGF-I receptor in human testis: an immunohistochemical study. Fertil Steril 1988, 49(4):666-669.
• [117]Cailleau J, Vermeire S, Verhoeven G: Independent control of the production of insulin-like growth factor I and its binding protein by cultured testicular cells. Mol Cell Endocrinol 1990, 69(1):79-89.
• [118]Naville D, Chatelain PG, Avallet O, Saez JM: Control of production of insulin-like growth factor I by pig Leydig and Sertoli cells cultured alone or together. Cell-cell interactions. Mol Cell Endocrinol 1990, 70(3):217-224.
• [119]Spiteri-Grech J, Bartlett JM, Nieschlag E: Regulation of testicular insulin-like growth factor-I in pubertal growth hormone-deficient male rats. J Endocrinol 1991, 131(2):279-285.
• [120]Perrard-Sapori MH, Chatelain PG, Jaillard C, Saez JM: Characterization and regulation of somatomedin-C/insulin-like growth factor I (Sm-C/IGF-I) receptors on cultured pig Leydig cells. Effects of Sm-C/IGF-I on luteotropin receptors and steroidogenesis. Eur J Biochem / FEBS 1987, 165(1):209-214.
• [121]Lin T, Haskell J, Vinson N, Terracio L: Characterization of insulin and insulin-like growth factor I receptors of purified Leydig cells and their role in steroidogenesis in primary culture: a comparative study. Endocrinology 1986, 119(4):1641-1647.
• [122]Saez JM: Leydig cells: endocrine, paracrine, and autocrine regulation. Endocr Rev 1994, 15(5):574-626.
• [123]Lin T: Insulin-like growth factor-I regulation of the leydig cell. In The leyding cell. Edited by Payne A, Hardy M, Russell L. Cache River Press, Vienna; 1996:477-491. vol. 1
• [124]Baker J, Hardy MP, Zhou J, Bondy C, Lupu F, Bellve AR, Efstratiadis A: Effects of an Igf1 gene null mutation on mouse reproduction. Mol Endocrinol 1996, 10(7):903-918.
• [125]Gelber SJ, Hardy MP, Mendis-Handagama SM, Casella SJ: Effects of insulin-like growth factor-I on androgen production by highly purified pubertal and adult rat Leydig cells. J Androl 1992, 13(2):125-130.
• [126]Adashi EY, Resnick CE, Hurwitz A, Ricciardelli E, Hernandez ER, Roberts CT, LeRoith D, Rosenfeld R: The ovarian and testicular IGF-I system: a comparative analysis. In Spermatogenesis-Fertilization-Contraception: Molecular, Cellular and Endocrine Events in Male Reproduction. Edited by Nieschlag E, Habenicht UF. Springer-Verlag, Berlin; 1992:143-168.
• [127]Giudice LC, Saleh W: Growth factors in reproduction. Trends in endocrinology and metabolism: TEM 1995, 6(2):60-69.
• [128]Nef S, Verma-Kurvari S, Merenmies J, Vassalli JD, Efstratiadis A, Accili D, Parada LF: Testis determination requires insulin receptor family function in mice. Nature 2003, 426(6964):291-295.
• [129]Villalpando I, Lopez-Olmos V: Insulin-like growth factor I (IGF-I) regulates endocrine activity of the embryonic testis in the mouse. J Steroid Biochem Mol Biol 2003, 86(2):151-158.
• [130]Tapanainen J, Kuopio T, Pelliniemi LJ, Huhtaniemi I: Rat testicular endogenous steroids and number of leydig cells between the fetal period and sexual maturity. Biol Reprod 1984, 31(5):1027-1035.
• [131]Lin T, Blaisdell J, Haskell JF: Type I IGF receptors of leydig cells are upregulated by human chorionic gonadotropin. Biochem Biophys Res Commun 1987, 149(3):852-858.
• [132]Moore A, Morris ID: The involvement of insulin-like growth factor-I in local control of steroidogenesis and DNA synthesis of leydig and non-leydig cells in the rat testicular interstitium. J Endocrinol 1993, 138(1):107-114.
• [133]Chuzel F, Clark AM, Avallet O, Saez JM: Transcriptional regulation of the lutropin/human choriogonadotropin receptor and three enzymes of steroidogenesis by growth factors in cultured pig leydig cells. European journal of biochemistry/FEBS 1996, 239(1):8-16.
• [134]Tiong TS, Herington AC: Tissue distribution, characterization, and regulation of messenger ribonucleic acid for growth hormone receptor and serum binding protein in the rat. Endocrinology 1991, 129(3):1628-1634.
• [135]Lobie PE, Breipohl W, Aragon JG, Waters MJ: Cellular localization of the growth hormone receptor/binding protein in the male and female reproductive systems. Endocrinology 1990, 126(4):2214-2221.
• [136]Godfrey P, Rahal JO, Beamer WG, Copeland NG, Jenkins NA, Mayo KE: GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nat Genet 1993, 4(3):227-232.
• [137]Chubb C: Sexual behavior and fertility of little mice. Biol Reprod 1987, 37(3):564-569.
• [138]Bach LA: The insulin-like growth factor system in kidney disease and hypertension. Curr Opin Nephrol Hypertens 2012, 21(1):86-91.
• [139]Rabkin R, Schaefer F: New concepts: growth hormone, insulin-like growth factor-I and the kidney. Growth Horm IGF Res 2004, 14(4):270-276.
• [140]Bridgewater DJ, Dionne JM, Butt MJ, Pin CL, Matsell DG: The role of the type I insulin-like growth factor receptor (IGF-IR) in glomerular integrity. Growth Horm IGF Res 2008, 18(1):26-37.
• [141]Martin AA, Tomas FM, Owens PC, Knowles SE, Ballard FJ, Read LC: IGF-I and its variant, des-(1–3)IGF-I, enhance growth in rats with reduced renal mass. Am J Physiol 1991, 261(4 Pt 2):F626-F633.
• [142]Hirschberg R: Insulin-like growth factor I in the kidney. Miner Electrolyte Metab 1996, 22(1–3):128-132.
• [143]Kumar PA, Brosius FC III, Menon RK: The glomerular podocyte as a target of growth hormone action: implications for the pathogenesis of diabetic nephropathy. Curr Diabetes Rev 2011, 7(1):50-55.
• [144]Yildiz B, Kural N, Colak O, Ak I, Akcar N: IGF-1, IGFBP-3, VEGF and MMP-9 levels and their potential relationship with renal functions in patients with compensatory renal growth. Clin Physiol Funct Imaging 2008, 28(2):107-112.
• [145]Mulroney SE, Haramati A, Werner H, Bondy C, Roberts CT Jr, LeRoith D: Altered expression of insulin-like growth factor-I (IGF-I) and IGF receptor genes after unilateral nephrectomy in immature rats. Endocrinology 1992, 130(1):249-256.
• [146]Landau D, Biada J, Chen Y, Sood S, Yakar S, Leroith D, Segev Y, Rabkin R: A marked deficiency in circulating and renal IGF-I peptide does not inhibit compensatory renal enlargement in uninephrectomized mice. Growth Horm IGF Res 2011, 21(5):279-284.
• [147]Delafontaine P, Bernstein KE, Alexander RW: Insulin-like growth factor I gene expression in vascular cells. Hypertension 1991, 17(5):693-699.
• [148]Guler HP, Zapf J, Scheiwiller E, Froesch ER: Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci U S A 1988, 85(13):4889-4893.
• [149]Wickman A, Isgaard J, Adams MA, Friberg P: Inhibition of nitric oxide in rats. Regulation of cardiovascular structure and expression of insulin-like growth factor I and its receptor messenger RNA. J Hypertens 1997, 15(7):751-759.
• [150]Chisalita SI, Johansson GS, Liefvendahl E, Back K, Arnqvist HJ: Human aortic smooth muscle cells are insulin resistant at the receptor level but sensitive to IGF1 and IGF2. J Mol Endocrinol 2009, 43(6):231-239.
• [151]Johansson GS, Chisalita SI, Arnqvist HJ: Human microvascular endothelial cells are sensitive to IGF-I but resistant to insulin at the receptor level. Mol Cell Endocrinol 2008, 296(1–2):58-63.
• [152]Pete G, Hu Y, Walsh M, Sowers J, Dunbar JC: Insulin-like growth factor-I decreases mean blood pressure and selectively increases regional blood flow in normal rats. Exp Biol Med 1996, 213(2):187-192.
• [153]Walsh MF, Barazi M, Pete G, Muniyappa R, Dunbar JC, Sowers JR: Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 1996, 137(5):1798-1803.
• [154]Copeland KC, Nair KS: Recombinant human insulin-like growth factor-I increases forearm blood flow. J Clin Endocrinol Metab 1994, 79(1):230-232.
• [155]Delafontaine P, Song YH, Li Y: Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004, 24(3):435-444.
• [156]Smith TJ: Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev 2010, 62(2):199-236.
• [157]O’Connor JC, McCusker RH, Strle K, Johnson RW, Dantzer R, Kelley KW: Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology. Cell Immunol 2008, 252(1–2):91-110.
• [158]Tsarfaty G, Longo DL, Murphy WJ: Human insulin-like growth factor I exerts hematopoietic growth-promoting effects after in vivo administration. Exp Hematol 1994, 22(13):1273-1277.
• [159]Murphy WJ, Durum SK, Longo DL: Human growth hormone promotes engraftment of murine or human T cells in severe combined immunodeficient mice. Proc Natl Acad Sci U S A 1992, 89(10):4481-4485.
• [160]Murphy WJ, Durum SK, Longo DL: Role of neuroendocrine hormones in murine T cell development. Growth hormone exerts thymopoietic effects in vivo. Journal of immunology 1992, 149(12):3851-3857.
• [161]de Mello-Coelho V, Villa-Verde DM, Dardenne M, Savino W: Pituitary hormones modulate cell-cell interactions between thymocytes and thymic epithelial cells. J Neuroimmunol 1997, 76(1–2):39-49.
• [162]Hinton PS, Peterson CA, Dahly EM, Ney DM: IGF-I alters lymphocyte survival and regeneration in thymus and spleen after dexamethasone treatment. Am J Physiol 1998, 274(4 Pt 2):R912-R920.
• [163]Walsh PT, Smith LM, O’Connor R: Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes. Immunology 2002, 107(4):461-471.
• [164]Tu W, Cheung PT, Lau YL: Insulin-like growth factor 1 promotes cord blood T cell maturation and inhibits its spontaneous and phytohemagglutinin-induced apoptosis through different mechanisms. J Immunol 2000, 165(3):1331-1336.
• [165]Hunt P, Eardley DD: Suppressive effects of insulin and insulin-like growth factor-1 (IGF1) on immune responses. J Immunol 1986, 136(11):3994-3999.
• [166]Gibson LF, Piktel D, Landreth KS: Insulin-like growth factor-1 potentiates expansion of interleukin-7-dependent pro-B cells. Blood 1993, 82(10):3005-3011.
• [167]Hadden JW, Malec PH, Coto J, Hadden EM: Thymic involution in aging. Prospects for correction. Ann N Y Acad Sci 1992, 673:231-239.
• [168]Miller RA: The aging immune system: primer and prospectus. Science 1996, 273(5271):70-74.
• [169]Lamberts SW, van den Beld AW, van der Lely AJ: The endocrinology of aging. Science 1997, 278(5337):419-424.
• [170]Chu YW, Schmitz S, Choudhury B, Telford W, Kapoor V, Garfield S, Howe D, Gress RE: Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion. Blood 2008, 112(7):2836-2846.
• [171]Landreth KS, Narayanan R, Dorshkind K: Insulin-like growth factor-I regulates pro-B cell differentiation. Blood 1992, 80(5):1207-1212.
• [172]Jardieu P, Clark R, Mortensen D, Dorshkind K: In vivo administration of insulin-like growth factor-I stimulates primary B lymphopoiesis and enhances lymphocyte recovery after bone marrow transplantation. J Immunol 1994, 152(9):4320-4327.
• [173]Clark R: The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Endocr Rev 1997, 18(2):157-179.
• [174]Robbins K, McCabe S, Scheiner T, Strasser J, Clark R, Jardieu P: Immunological effects of insulin-like growth factor-I–enhancement of immunoglobulin synthesis. Clin Exp Immunol 1994, 95(2):337-342.
• [175]Rom WN, Paakko P: Activated alveolar macrophages express the insulin-like growth factor-I receptor. Am J Respir Cell Mol Biol 1991, 4(5):432-439.
• [176]Resnik R: Intrauterine growth restriction. Obstet Gynecol 2002, 99(3):490-496.
• [177]Low JA, Handley-Derry MH, Burke SO, Peters RD, Pater EA, Killen HL, Derrick EJ: Association of intrauterine fetal growth retardation and learning deficits at age 9 to 11 years. Am J Obstet Gynecol 1992, 167(6):1499-1505.
• [178]Kramer MS, Olivier M, McLean FH, Willis DM, Usher RH: Impact of intrauterine growth retardation and body proportionality on fetal and neonatal outcome. Pediatrics 1990, 86(5):707-713.
• [179]Hattersley AT, Tooke JE: The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet 1999, 353(9166):1789-1792.
• [180]Barker DJ: The developmental origins of well-being. Philos Trans R Soc Lond B Biol Sci 2004, 359(1449):1359-1366.
• [181]Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J: Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994, 15(3):369-390.
• [182]Randhawa R, Cohen P: The role of the insulin-like growth factor system in prenatal growth. Mol Genet Metab 2005, 86(1–2):84-90.
• [183]Gluckman PD, Hanson MA: Maternal constraint of fetal growth and its consequences. Semin Fetal Neonatal Med 2004, 9(5):419-425.
• [184]Penrose LS: Data on the genetics of birth weight. Ann Eugen 1952, 16(4):378-381.
• [185]Setia S, Sridhar MG: Changes in GH/IGF-1 axis in intrauterine growth retardation: consequences of fetal programming? Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2009, 41(11):791-798.
• [186]Brosens JJ, Pijnenborg R, Brosens IA: The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. Am J Obstet Gynecol 2002, 187(5):1416-1423.
• [187]Miller HC: Prenatal factors affecting intrauterine growth retardation. Clin Perinatol 1985, 12(2):307-318.
• [188]Voigt HJ, Becker V: Doppler flow measurements and histomorphology of the placental bed in uteroplacental insufficiency. J Perinat Med 1992, 20(2):139-147.
• [189]Verhaeghe J, Bougoussa M, Van Herck E, de Zegher F, Hennen G, Igout A: Placental growth hormone and IGF-I in a pregnant woman with Pit-1 deficiency. Clin Endocrinol 2000, 53(5):645-647.
• [190]Reece EA, Wiznitzer A, Le E, Homko CJ, Behrman H, Spencer EM: The relation between human fetal growth and fetal blood levels of insulin-like growth factors I and II, their binding proteins, and receptors. Obstet Gynecol 1994, 84(1):88-95.
• [191]Koutsaki M, Sifakis S, Zaravinos A, Koutroulakis D, Koukoura O, Spandidos DA: Decreased placental expression of hPGH, IGF-I and IGFBP-1 in pregnancies complicated by fetal growth restriction. Growth Horm IGF Res 2011, 21(1):31-36.
• [192]de Zegher F, Francois I, van Helvoirt M, Van den Berghe G: Clinical review 89: Small as fetus and short as child: from endogenous to exogenous growth hormone. J Clin Endocrinol Metab 1997, 82(7):2021-2026.
• [193]Giudice LC, de Zegher F, Gargosky SE, Dsupin BA, de las Fuentes L, Crystal RA, Hintz RL, Rosenfeld RG: Insulin-like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine growth. J Clin Endocrinol Metab 1995, 80(5):1548-1555.
• [194]Kajimura S, Aida K, Duan C: Insulin-like growth factor-binding protein-1 (IGFBP-1) mediates hypoxia-induced embryonic growth and developmental retardation. Proc Natl Acad Sci U S A 2005, 102(4):1240-1245.
• [195]Woods KA, van Helvoirt M, Ong KK, Mohn A, Levy J, de Zegher F, Dunger DB: The somatotropic axis in short children born small for gestational age: relation to insulin resistance. Pediatr Res 2002, 51(1):76-80.
• [196]Jaquet D, Vidal H, Hankard R, Czernichow P, Levy-Marchal C: Impaired regulation of glucose transporter 4 gene expression in insulin resistance associated with in utero undernutrition. J Clin Endocrinol Metab 2001, 86(7):3266-3271.
• [197]Han VK, Carter AM: Control of growth and development of the feto-placental unit. Curr Opin Pharmacol 2001, 1(6):632-640.
• [198]Vehaskari VM, Aviles DH, Manning J: Prenatal programming of adult hypertension in the rat. Kidney Int 2001, 59(1):238-245.
• [199]Laron Z, Pertzelan A, Mannheimer S: Genetic pituitary dwarfism with high serum concentation of growth hormone–a new inborn error of metabolism? Israel J Med Sci 1966, 2(2):152-155.
• [200]Laron Z: Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958–2003. J Clin Endocrinol Metab 2004, 89(3):1031-1044.
• [201]Laron Z, Parks JS (Eds): Lessons from Laron Syndrome (LS) 1996-1992 In Pediatr Adolesc Endocrinol. Karger, Basel; 1993:237-243.
• [202]Rosenbloom AL: Growth hormone insensitivity: physiologic and genetic basis, phenotype, and treatment. J Pediatr 1999, 135(3):280-289.
• [203]Feinberg MS, Scheinowitz M, Laron Z: Echocardiographic dimensions and function in adults with primary growth hormone resistance (laron syndrome). Am J Cardiol 2000, 85(2):209-213.
• [204]Brat O, Ziv I, Klinger B, Avraham M, Laron Z: Muscle force and endurance in untreated and human growth hormone or insulin-like growth factor-I-treated patients with growth hormone deficiency or laron syndrome. Horm Res 1997, 47(2):45-48.
• [205]Guevara-Aguirre J, Rosenbloom AL, Vaccarello MA, Fielder PJ, de la Vega A, Diamond FB Jr, Rosenfeld RG: Growth hormone receptor deficiency (laron syndrome): clinical and genetic characteristics. Acta Paediatr Scand Suppl 1991, 377:96-103.
• [206]Laron Z: Laron-type dwarfism (hereditary somatomedin deficiency): a review. In Advances in internal medicine and pediatrics. Edited by Frick P, Harnack GA, Kochsieck K, Martini GA, Prader A. Springer, Berlin; 1984:117-150.
• [207]Lurie R, Ben-Amitai D, Laron Z: Laron syndrome (primary growth hormone insensitivity): a unique model to explore the effect of insulin-like growth factor 1 deficiency on human hair. Dermatology 2004, 208(4):314-318.
• [208]Johnston LB, Woods KA, Rose SJ, Clark AJ, Savage MO: The broad spectrum of inherited growth hormone insensitivity syndrome. Trends Endocrin Met: TEM 1998, 9(6):228-232.
• [209]Quiroga J, Beloqui O, Castilla A: Cirrhosis. In Hepatobilliary diseases. Edited by Prieto J, Rodes J, Shafritz DA. Springer-Verlag, Berlin; 1992:323-415.
• [210]Bruguera-Cortada M, Rodes-Teixidor J: Cirrosis hepática compensada. In Tratamiento de las enfermedades hepáticas. Edited by Bruguera-Cortada M, Mino-Fugarolas G, Pons-Romero F, Moreno-Otero R. Asociación Española para el Estudio del Hígado, Spain; 1997:45-50.
• [211]Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, Caballeria J, Rodes J, Rozman C: Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987, 7(1):122-128.
• [212]Sheppard MS, Minuk GY, Bhaumick B, Bala RM: Insulin-like growth factors (IGF) in liver disease: differential changes of IGF-I and IGF-II. Clin Invest Med Medecine clinique et experimentale 1987, 10(2):49-53.
• [213]Caufriez A, Reding P, Urbain D, Golstein J, Copinschi G: Insulin-like growth factor I: a good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis. J Endocrinol Invest 1991, 14(4):317-321.
• [214]Assy N, Hochberg Z, Amit T, Shen-Orr Z, Enat R, Baruch Y: Growth hormone-stimulated insulin-like growth factor (IGF) I and IGF-binding protein-3 in liver cirrhosis. J Hepatol 1997, 27(5):796-802.
• [215]Caregaro L, Alberino F, Amodio P, Merkel C, Angeli P, Plebani M, Bolognesi M, Gatta A: Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis. Nutrition 1997, 13(3):185-190.
• [216]Chang TC, Lin JJ, Yu SC, Chang TJ: Absence of growth-hormone receptor in hepatocellular carcinoma and cirrhotic liver. Hepatology 1990, 11(1):123-126.
• [217]Inaba T, Saito H, Inoue T, Han I, Furukawa S, Matsuda T, Ikeda S, Muto T: Growth hormone/insulin-like growth factor 1 axis alterations contribute to disturbed protein metabolism in cirrhosis patients after hepatectomy. J Hepatol 1999, 31(2):271-276.
• [218]Moller S, Becker U, Juul A, Skakkebaek NE, Christensen E: Prognostic value of insulinlike growth factor I and its binding protein in patients with alcohol-induced liver disease. EMALD group. Hepatology 1996, 23(5):1073-1078.
• [219]Picardi A, de Oliveira AC, Muguerza B, Tosar A, Quiroga J, Castilla-Cortazar I, Santidrian S, Prieto J: Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis. J Hepatol 1997, 26(1):191-202.
• [220]Pascual M, Castilla-Cortazar I, Urdaneta E, Quiroga J, Garcia M, Picardi A, Prieto J: Altered intestinal transport of amino acids in cirrhotic rats: the effect of insulin-like growth factor-I. Am J Physiol Gastrointest Liver Physiol 2000, 279(2):G319-G324.
• [221]Castilla-Cortazar I, Prieto J, Urdaneta E, Pascual M, Nunez M, Zudaire E, Garcia M, Quiroga J, Santidrian S: Impaired intestinal sugar transport in cirrhotic rats: correction by low doses of insulin-like growth factor I. Gastroenterology 1997, 113(4):1180-1187.
• [222]Castilla-Cortazar I, Pascual M, Urdaneta E, Pardo J, Puche JE, Vivas B, Diaz-Casares A, Garcia M, Diaz-Sanchez M, Varela-Nieto I, et al.: Jejunal microvilli atrophy and reduced nutrient transport in rats with advanced liver cirrhosis: improvement by insulin-like growth factor I. BMC Gastroenterol 2004, 4:12. BioMed Central Full Text
• [223]Castilla-Cortazar I, Garcia M, Muguerza B, Quiroga J, Perez R, Santidrian S, Prieto J: Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology 1997, 113(5):1682-1691.
• [224]Lorenzo-Zuniga V, Rodriguez-Ortigosa CM, Bartoli R, Martinez-Chantar ML, Martinez-Peralta L, Pardo A, Ojanguren I, Quiroga J, Planas R, Prieto J: Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats. Gut 2006, 55(9):1306-1312.
• [225]Cemborain A, Castilla-Cortazar I, Garcia M, Quiroga J, Muguerza B, Picardi A, Santidrian S, Prieto J: Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol 1998, 28(1):122-131.
• [226]Cemborain A, Castilla-Cortazar I, Garcia M, Muguerza B, Delgado G, Diaz-Sanchez M, Picardi A: Effects of IGF-I treatment on osteopenia in rats with advanced liver cirrhosis. J Physiol Biochem 2000, 56(2):91-99.
• [227]Castilla-Cortazar I, Garcia M, Quiroga J, Diez N, Diez-Caballero F, Calvo A, Diaz M, Prieto J: Insulin-like growth factor-I reverts testicular atrophy in rats with advanced cirrhosis. Hepatology 2000, 31(3):592-600.
• [228]Castilla-Cortazar I, Diez N, Garcia-Fernandez M, Puche JE, Diez-Caballero F, Quiroga J, Diaz-Sanchez M, Castilla A, Casares AD, Varela-Nieto I, et al.: Hematotesticular barrier is altered from early stages of liver cirrhosis: effect of insulin-like growth factor 1. World J Gastroentero: WJG 2004, 10(17):2529-2534.
• [229]Castilla-Cortazar I, Aliaga-Montilla MA, Salvador J, Garcia M, Delgado G, Gonzalez-Baron S, Quiroga J, Prieto J: Insulin-like growth factor-I restores the reduced somatostatinergic tone controlling growth hormone secretion in cirrhotic rats. Liver 2001, 21(6):405-409.
• [230]Garcia-Fernandez M, Castilla-Cortazar I, Diaz-Sanchez M, Navarro I, Puche JE, Castilla A, Casares AD, Clavijo E, Gonzalez-Baron S: Antioxidant effects of insulin-like growth factor-I (IGF-I) in rats with advanced liver cirrhosis. BMC Gastroenterol 2005, 5:7. BioMed Central Full Text
• [231]Muguerza B, Castilla-Cortazar I, Garcia M, Quiroga J, Santidrian S, Prieto J: Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats. Biochim Biophys Acta 2001, 1536(2–3):185-195.
• [232]Perez R, Garcia-Fernandez M, Diaz-Sanchez M, Puche JE, Delgado G, Conchillo M, Muntane J, Castilla-Cortazar I: Mitochondrial protection by low doses of insulin-like growth factor- I in experimental cirrhosis. World J Gastroentero: WJG 2008, 14(17):2731-2739.
• [233]Tutau F, Rodriguez-Ortigosa C, Puche JE, Juanarena N, Monreal I, Garcia Fernandez M, Clavijo E, Castilla A, Castilla-Cortazar I: Enhanced actions of insulin-like growth factor-I and interferon-alpha co-administration in experimental cirrhosis. Liver International: official journal of the International Association for the Study of the Liver 2009, 29(1):37-46.
• [234]Mirpuri E, Garcia-Trevijano ER, Castilla-Cortazar I, Berasain C, Quiroga J, Rodriguez-Ortigosa C, Mato JM, Prieto J, Avila MA: Altered liver gene expression in CCl4-cirrhotic rats is partially normalized by insulin-like growth factor-I. Int J Biochem Cell Biol 2002, 34(3):242-252.
• [235]Futterman LG, Lemberg L: The framingham heart study: a pivotal legacy of the last millennium. American journal of critical care: an official publication, American Association of Critical-Care Nurses 2000, 9(2):147-151.
• [236]Fries JF: Aging, natural death, and the compression of morbidity. N Eng J Med 1980, 303(3):130-135.
• [237]Bartke A, Chandrashekar V, Dominici F, Turyn D, Kinney B, Steger R, Kopchick JJ: Insulin-like growth factor 1 (IGF-1) and aging: controversies and new insights. Biogerontology 2003, 4(1):1-8.
• [238]Weinert BT, Timiras PS: Invited review: theories of aging. J Appl Physiol 2003, 95(4):1706-1716.
• [239]Boveris A, Oshino N, Chance B: The cellular production of hydrogen peroxide. Biochem J 1972, 128(3):617-630.
• [240]Giulivi C, Boveris A, Cadenas E: Reactive oxygen species in biological systems: an interdisciplinary approach. Edited by Gilbert D, Colton C. Kluwer Academic/Plenum Publishers, New York; 1999:77-102.
• [241]Van Raamsdonk JM, Meng Y, Camp D, Yang W, Jia X, Benard C, Hekimi S: Decreased energy metabolism extends life span in Caenorhabditis elegans without reducing oxidative damage. Genetics 2010, 185(2):559-571.
• [242]Hodge RD, D’Ercole AJ, O’Kusky JR: Insulin-like growth factor-I (IGF-I) inhibits neuronal apoptosis in the developing cerebral cortex in vivo. International journal of developmental neuroscience: the official journal of the International Society for Developmental Neuroscience 2007, 25(4):233-241.
• [243]Ye P, Xing Y, Dai Z, D’Ercole AJ: In vivo actions of insulin-like growth factor-I (IGF-I) on cerebellum development in transgenic mice: evidence that IGF-I increases proliferation of granule cell progenitors. Brain Res Dev Brain Res 1996, 95(1):44-54.
• [244]Chrysis D, Calikoglu AS, Ye P, D’Ercole AJ: Insulin-like growth factor-I overexpression attenuates cerebellar apoptosis by altering the expression of Bcl family proteins in a developmentally specific manner. J Neurosci 2001, 21(5):1481-1489.
• [245]Moverare-Skrtic S, Svensson J, Karlsson MK, Orwoll E, Ljunggren O, Mellstrom D, Ohlsson C: Serum insulin-like growth factor-I concentration is associated with leukocyte telomere length in a population-based cohort of elderly men. J Clin Endocrinol Metab 2009, 94(12):5078-5084.
• [246]Barbieri M, Paolisso G, Kimura M, Gardner JP, Boccardi V, Papa M, Hjelmborg JV, Christensen K, Brimacombe M, Nawrot TS, et al.: Higher circulating levels of IGF-1 are associated with longer leukocyte telomere length in healthy subjects. Mech Ageing Dev 2009, 130(11–12):771-776.
• [247]Fitzpatrick AL, Kronmal RA, Gardner JP, Psaty BM, Jenny NS, Tracy RP, Walston J, Kimura M, Aviv A: Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol 2007, 165(1):14-21.
• [248]Vasan RS, Demissie S, Kimura M, Cupples LA, Rifai N, White C, Wang TJ, Gardner JP, Cao X, Benjamin EJ, et al.: Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the framingham heart study. Circulation 2008, 117(9):1138-1144.
• [249]Blakesley VA, Butler AA, Koval AP, Okubo Y, LeRoith D: IGF-1 receptor function: transducing the igf-1 signal into intracellular events. In The IGF system. Edited by Rosenfeld R, Roberts C. Humana Press, New Jersey; 1999:143-164.
• [250]White MF: The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 1998, 182(1–2):3-11.
• [251]Skolnik EY, Batzer A, Li N, Lee CH, Lowenstein E, Mohammadi M, Margolis B, Schlessinger J: The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 1993, 260(5116):1953-1955.
• [252]Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR: Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp 70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol 1994, 14(7):4902-4911.
• [253]Kohn AD, Summers SA, Birnbaum MJ, Roth RA: Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 1996, 271(49):31372-31378.
• [254]Zhang X, Gan L, Pan H, Guo S, He X, Olson ST, Mesecar A, Adam S, Unterman TG: Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem 2002, 277(47):45276-45284.
• [255]Van Der Heide LP, Hoekman MF, Smidt MP: The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 2004, 380(Pt 2):297-309.
• [256]Hribal ML, Nakae J, Kitamura T, Shutter JR, Accili D: Regulation of insulin-like growth factor-dependent myoblast differentiation by Foxo forkhead transcription factors. J Cell Biol 2003, 162(4):535-541.
• [257]Gilley J, Coffer PJ, Ham J: FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 2003, 162(4):613-622.
• [258]Martinez-Gac L, Marques M, Garcia Z, Campanero MR, Carrera AC: Control of cyclin G2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead. Mol Cell Biol 2004, 24(5):2181-2189.
• [259]Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ Jr, DiStefano PS, Chiang LW, Greenberg ME: DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 2002, 296(5567):530-534.
• [260]Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, et al.: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303(5666):2011-2015.
• [261]Facchini FS, Hua N, Abbasi F, Reaven GM: Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001, 86(8):3574-3578.
• [262]DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14(3):173-194.
• [263]Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37(12):1595-1607.
• [264]Umegaki H: Neurodegeneration in diabetes mellitus. Adv Exp Med Biol 2012, 724:258-265.
• [265]Bosco D, Plastino M, Cristiano D, Colica C, Ermio C, De Bartolo M, Mungari P, Fonte G, Consoli D, Consoli A, et al.: Dementia is associated with insulin resistance in patients with Parkinson’s disease. J Neurol Sci 2012, 315(1–2):39-43.
• [266]Longo VD: Linking sirtuins, IGF-I signaling, and starvation. Exp Gerontol 2009, 44(1–2):70-74.
• [267]Rincon M, Muzumdar R, Atzmon G, Barzilai N: The paradox of the insulin/IGF-1 signaling pathway in longevity. Mech Ageing Dev 2004, 125(6):397-403.
• [268]Barzilai N, Huffman DM, Muzumdar RH, Bartke A: The critical role of metabolic pathways in aging. Diabetes 2012, 61(6):1315-1322.
• [269]Tang BL: SIRT1, neuronal cell survival and the insulin/IGF-1 aging paradox. Neurobiol Aging 2006, 27(3):501-505.
• [270]Ungvari Z, Csiszar A: The emerging role of IGF-1 deficiency in cardiovascular aging: recent advances. The journals of gerontology Series A, Biological sciences and medical sciences 2012, 67(6):599-610.
• [271]Rosen T, Bengtsson BA: Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336(8710):285-288.
• [272]Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D: The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004, 89(1):114-120.
• [273]Conti E, Carrozza C, Capoluongo E, Volpe M, Crea F, Zuppi C, Andreotti F: Insulin-like growth factor-1 as a vascular protective factor. Circulation 2004, 110(15):2260-2265.
• [274]Sesti G, Sciacqua A, Cardellini M, Marini MA, Maio R, Vatrano M, Succurro E, Lauro R, Federici M, Perticone F: Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 2005, 28(1):120-125.
• [275]Spallarossa P, Brunelli C, Minuto F, Caruso D, Battistini M, Caponnetto S, Cordera R: Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol 1996, 77(2):200-202.
• [276]Johnsen SP, Hundborg HH, Sorensen HT, Orskov H, Tjonneland A, Overvad K, Jorgensen JO: Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab 2005, 90(11):5937-5941.
• [277]Vasan RS, Sullivan LM, D’Agostino RB, Roubenoff R, Harris T, Sawyer DB, Levy D, Wilson PW: Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med 2003, 139(8):642-648.
• [278]Conti E, Andreotti F, Sciahbasi A, Riccardi P, Marra G, Menini E, Ghirlanda G, Maseri A: Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. J Am Coll Cardiol 2001, 38(1):26-32.
• [279]Galderisi M, Caso P, Cicala S, De Simone L, Barbieri M, Vitale G, de Divitiis O, Paolisso G: Positive association between circulating free insulin-like growth factor-1 levels and coronary flow reserve in arterial systemic hypertension. Am J Hypertens 2002, 15(9):766-772.
• [280]Paolisso G, Ammendola S, Del Buono A, Gambardella A, Riondino M, Tagliamonte MR, Rizzo MR, Carella C, Varricchio M: Serum levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in healthy centenarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function. J Clin Endocrinol Metab 1997, 82(7):2204-2209.
• [281]Bailey-Downs LC, Mitschelen M, Sosnowska D, Toth P, Pinto JT, Ballabh P, Valcarcel-Ares MN, Farley J, Koller A, Henthorn JC, et al.: Liver-specific knockdown of IGF-1 decreases vascular oxidative stress resistance by impairing the Nrf2-dependent antioxidant response: a novel model of vascular aging. The journals of gerontology Series A, Biological sciences and medical sciences 2012, 67(4):313-329.
• [282]Li Q, Ceylan-Isik AF, Li J, Ren J: Deficiency of insulin-like growth factor 1 reduces sensitivity to aging-associated cardiomyocyte dysfunction. Rejuvenation Res 2008, 11(4):725-733.
• [283]Li Q, Wu S, Li SY, Lopez FL, Du M, Kajstura J, Anversa P, Ren J: Cardiac-specific overexpression of insulin-like growth factor 1 attenuates aging-associated cardiac diastolic contractile dysfunction and protein damage. Am J Physiol Heart Circ Physiol 2007, 292(3):H1398-H1403.
• [284]Li Q, Ren J: Influence of cardiac-specific overexpression of insulin-like growth factor 1 on lifespan and aging-associated changes in cardiac intracellular Ca2+ homeostasis, protein damage and apoptotic protein expression. Aging Cell 2007, 6(6):799-806.
• [285]Vinciguerra M, Santini MP, Claycomb WC, Ladurner AG, Rosenthal N: Local IGF-1 isoform protects cardiomyocytes from hypertrophic and oxidative stresses via SirT1 activity. Aging 2010, 2(1):43-62.
• [286]Ungvari Z, Gautam T, Koncz P, Henthorn JC, Pinto JT, Ballabh P, Yan H, Mitschelen M, Farley J, Sonntag WE, et al.: Vasoprotective effects of life span-extending peripubertal GH replacement in Lewis dwarf rats. The journals of gerontology Series A, Biological sciences and medical sciences 2010, 65(11):1145-1156.
• [287]Urbanek K, Rota M, Cascapera S, Bearzi C, Nascimbene A, De Angelis A, Hosoda T, Chimenti S, Baker M, Limana F, et al.: Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res 2005, 97(7):663-673.
• [288]Torella D, Rota M, Nurzynska D, Musso E, Monsen A, Shiraishi I, Zias E, Walsh K, Rosenzweig A, Sussman MA, et al.: Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ Res 2004, 94(4):514-524.
• [289]Ungvari Z, Kaley G, de Cabo R, Sonntag WE, Csiszar A: Mechanisms of vascular aging: new perspectives. The journals of gerontology Series A, Biological sciences and medical sciences 2010, 65(10):1028-1041.
• [290]Li Y, Wu H, Khardori R, Song YH, Lu YW, Geng YJ: Insulin-like growth factor-1 receptor activation prevents high glucose-induced mitochondrial dysfunction, cytochrome-c release and apoptosis. Biochem Biophys Res Commun 2009, 384(2):259-264.
• [291]Rivard A, Fabre JE, Silver M, Chen D, Murohara T, Kearney M, Magner M, Asahara T, Isner JM: Age-dependent impairment of angiogenesis. Circulation 1999, 99(1):111-120.
• [292]Thum T, Hoeber S, Froese S, Klink I, Stichtenoth DO, Galuppo P, Jakob M, Tsikas D, Anker SD, Poole-Wilson PA, et al.: Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res 2007, 100(3):434-443.
• [293]Csiszar A, Ungvari Z, Edwards JG, Kaminski P, Wolin MS, Koller A, Kaley G: Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res 2002, 90(11):1159-1166.
• [294]Csiszar A, Labinskyy N, Perez V, Recchia FA, Podlutsky A, Mukhopadhyay P, Losonczy G, Pacher P, Austad SN, Bartke A, et al.: Endothelial function and vascular oxidative stress in long-lived GH/IGF-deficient Ames dwarf mice. Am J Physiol Heart Circ Physiol 2008, 295(5):H1882-H1894.
• [295]Cittadini A, Monti MG, Castiello MC, D’Arco E, Galasso G, Sorriento D, Saldamarco L, De Paulis A, Napoli R, Iaccarino G, et al.: Insulin-like growth factor-1 protects from vascular stenosis and accelerates re-endothelialization in a rat model of carotid artery injury. J Thromb Haemost: JTH 2009, 7(11):1920-1928.
• [296]Clemmons DR: Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007, 6(10):821-833.
• [297]Higashi Y, Sukhanov S, Anwar A, Shai SY, Delafontaine P: IGF-1, oxidative stress and atheroprotection. Trends Endocrin Met: TEM 2010, 21(4):245-254.
• [298]Ross R: Atherosclerosis–an inflammatory disease. N Eng J Med 1999, 340(2):115-126.
• [299]Jeschke MG, Barrow RE, Herndon DN: Insulinlike growth factor I plus insulinlike growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children. Ann Surg 2000, 231(2):246-252.
• [300]National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A: Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106(25):3143-3421.
• [301]Akanji AO, Smith RJ: The insulin-like growth factor system, metabolic syndrome, and cardiovascular disease risk. Metab Syndr Relat Disord 2012, 10(1):3-13.
• [302]Bideci A, Camurdan MO, Cinaz P, Dursun H, Demirel F: Serum zinc, insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2005, 18(10):1007-1011.
• [303]Simpson HL, Jackson NC, Shojaee-Moradie F, Jones RH, Russell-Jones DL, Sonksen PH, Dunger DB, Umpleby AM: Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes. J Clin Endocrinol Metab 2004, 89(1):425-432.
• [304]Saukkonen T, Shojaee-Moradie F, Williams RM, Amin R, Yuen KC, Watts A, Acerini CL, Umpleby AM, Dunger DB: Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes. Diabetes 2006, 55(8):2365-2370.
• [305]Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J: The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 2000, 85(4):1518-1524.
• [306]Kolaczynski JW, Caro JF: Insulin-like growth factor-1 therapy in diabetes: physiologic basis, clinical benefits, and risks. Ann Intern Med 1994, 120(1):47-55.
• [307]Paolisso G, Tagliamonte MR, Rizzo MR, Giugliano D: Advancing age and insulin resistance: new facts about an ancient history. Eur J Clin Invest 1999, 29(9):758-769.
• [308]Schini-Kerth VB: Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells. J Endocrinol Invest 1999, 22(5 Suppl):82-88.
• [309]Gomez JM, Maravall FJ, Gomez N, Navarro MA, Casamitjana R, Soler J: Interactions between serum leptin, the insulin-like growth factor-I system, and sex, age, anthropometric and body composition variables in a healthy population randomly selected. Clin Endocrinol 2003, 58(2):213-219.
• [310]Conti E, Andreotti F, Sestito A, Riccardi P, Menini E, Crea F, Maseri A, Lanza GA: Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries. Am J Cardiol 2002, 89(8):973-975.
• [311]Rasmussen MH, Hvidberg A, Juul A, Main KM, Gotfredsen A, Skakkebaek NE, Hilsted J, Skakkebae NE: Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J Clin Endocrinol Metab 1995, 80(4):1407-1415.
• [312]Twickler MT, Cramer MJ, Koppeschaar HP: Unraveling Reaven’s syndrome X: serum insulin-like growth factor-I and cardiovascular disease. Circulation 2003, 107(20):e190-e192. author reply e190-192
• [313]Scheidegger KJ, James RW, Delafontaine P: Differential effects of low density lipoproteins on insulin-like growth factor-1 (IGF-1) and IGF-1 receptor expression in vascular smooth muscle cells. J Biol Chem 2000, 275(35):26864-26869.
• [314]Malik J, Stulc T, Wichterle D, Melenovsky V, Chytilova E, Lacinova Z, Marek J, Ceska R: Hyperlipidemia is associated with altered levels of insulin-like growth factor-I. Physiological research / Academia Scientiarum Bohemoslovaca 2008, 57(6):919-925.
• [315]Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ: Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002, 359(9319):1740-1745.
• [316]Efstratiadis G, Tsiaousis G, Athyros VG, Karagianni D, Pavlitou-Tsiontsi A, Giannakou-Darda A, Manes C: Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. Angiology 2006, 57(3):303-311.
• [317]Teramukai S, Rohan T, Eguchi H, Oda T, Shinchi K, Kono S: Anthropometric and behavioral correlates of insulin-like growth factor I and insulin-like growth factor binding protein 3 in middle-aged Japanese men. Am J Epidemiol 2002, 156(4):344-348.
• [318]Trejo JL, Carro E, Nunez A, Torres-Aleman I: Sedentary life impairs self-reparative processes in the brain: the role of serum insulin-like growth factor-I. Rev Neurosci 2002, 13(4):365-374.
• [319]Unden AL, Elofsson S, Knox S, Lewitt MS, Brismar K: IGF-I in a normal population: relation to psychosocial factors. Clin Endocrinol 2002, 57(6):793-803.
• [320]Dandona P, Aljada A, Dhindsa S, Garg R: Insulin as an anti-inflammatory and antiatherosclerotic hormone. Clin Cornerstone 2003, (Suppl 4):S13-S20. PMID:14986904
• [321]Gillespie CM, Merkel AL, Martin AA: Effects of insulin-like growth factor-I and LR3IGF-I on regional blood flow in normal rats. J Endocrinol 1997, 155(2):351-358.
• [322]Izhar U, Hasdai D, Richardson DM, Cohen P, Lerman A: Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels in vitro. Coron Artery Dis 2000, 11(1):69-76.
• [323]Utriainen T, Nuutila P, Takala T, Vicini P, Ruotsalainen U, Ronnemaa T, Tolvanen T, Raitakari M, Haaparanta M, Kirvela O, et al.: Intact insulin stimulation of skeletal muscle blood flow, its heterogeneity and redistribution, but not of glucose uptake in non-insulin-dependent diabetes mellitus. J Clin Invest 1997, 100(4):777-785.
• [324]Gasperi M, Castellano AE: Growth hormone/insulin-like growth factor I axis in neurodegenerative diseases. J Endocrinol Invest 2010, 33(8):587-591.
• [325]Torres-Aleman I: Targeting insulin-like growth factor-1 to treat Alzheimer’s disease. Expert Opin Ther Targets 2007, 11(12):1535-1542.
• [326]Carro E, Trejo JL, Gerber A, Loetscher H, Torrado J, Metzger F, Torres-Aleman I: Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol Aging 2006, 27(9):1250-1257.
• [327]Cheng CM, Tseng V, Wang J, Wang D, Matyakhina L, Bondy CA: Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology 2005, 146(12):5086-5091.
• [328]Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al.: Inflammation and alzheimer’s disease. Neurobiol Aging 2000, 21(3):383-421.
• [329]Miranda S, Opazo C, Larrondo LF, Munoz FJ, Ruiz F, Leighton F, Inestrosa NC: The role of oxidative stress in the toxicity induced by amyloid beta-peptide in alzheimer’s disease. Prog Neurobiol 2000, 62(6):633-648.
• [330]Corbo M, Lunetta C, Magni P, Dozio E, Ruscica M, Adobbati L, Silani V: Free insulin-like growth factor (IGF)-1 and IGF-binding proteins-2 and −3 in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients. Eur J Neurol: the official journal of the European Federation of Neurological Societies 2010, 17(3):398-404.
• [331]Lunetta C, Serafini M, Prelle A, Magni P, Dozio E, Ruscica M, Sassone J, Colciago C, Moggio M, Corbo M, et al.: Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients. Muscle Nerve 2012, 45(2):200-208.
• [332]Kerkhoff H, Hassan SM, Troost D, Van Etten RW, Veldman H, Jennekens FG: Insulin-like and fibroblast growth factors in spinal cords, nerve roots and skeletal muscle of human controls and patients with amyotrophic lateral sclerosis. Acta Neuropathol 1994, 87(4):411-421.
• [333]Ozdinler PH, Macklis JD: IGF-I specifically enhances axon outgrowth of corticospinal motor neurons. Nat Neurosci 2006, 9(11):1371-1381.
• [334]Xiao Q, Zhao W, Beers DR, Yen AA, Xie W, Henkel JS, Appel SH: Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia. J Neurochem 2007, 102(6):2008-2019.
• [335]Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, Silani V, Vos PE, Wokke JH, Dobbins T: A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I study group. Neurology 1998, 51(2):583-586.
• [336]Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Murphy MF, Natter HM, Norris FH, Rudnicki SA: Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The north america ALS/IGF-I study group. Neurology 1997, 49(6):1621-1630.
• [337]Donnan GA, Fisher M, Macleod M, Davis SM: Stroke. Lancet 2008, 371(9624):1612-1623.
• [338]Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997, 349(9061):1269-1276.
• [339]De Smedt A, Brouns R, Uyttenboogaart M, De Raedt S, Moens M, Wilczak N, Luijckx GJ, De Keyser J: Insulin-like growth factor I serum levels influence ischemic stroke outcome. Stroke; a journal of cerebral circulation 2011, 42(8):2180-2185.
• [340]Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM: Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 1997, 46(1):75-81.
• [341]Sonntag WE, Lynch CD, Cooney PT, Hutchins PM: Decreases in cerebral microvasculature with age are associated with the decline in growth hormone and insulin-like growth factor 1. Endocrinology 1997, 138(8):3515-3520.
• [342]Sonntag WE, Lynch C, Thornton P, Khan A, Bennett S, Ingram R: The effects of growth hormone and IGF-1 deficiency on cerebrovascular and brain ageing. J Anat 2000, 197(Pt 4):575-585.
• [343]Lopez-Lopez C, LeRoith D, Torres-Aleman I: Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc Natl Acad Sci U S A 2004, 101(26):9833-9838.
• [344]Gonzalez C, Diaz F, Alonso A: Neuroprotective effects of estrogens: cross-talk between estrogen and intracellular insulin signalling. Infect Disord Drug Targets 2008, 8(1):65-67.
• [345]Garcia-Segura LM, Arevalo MA, Azcoitia I: Interactions of estradiol and insulin-like growth factor-I signalling in the nervous system: new advances. Prog Brain Res 2010, 181:251-272.
• [346]Fernandez AM, Torres-Aleman I: The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci 2012, 13(4):225-239.
• [347]Ozdemir D, Baykara B, Aksu I, Kiray M, Sisman AR, Cetin F, Dayi A, Gurpinar T, Uysal N, Arda MN: Relationship between circulating IGF-1 levels and traumatic brain injury-induced hippocampal damage and cognitive dysfunction in immature rats. Neurosci Lett 2012, 507(1):84-89.
• [348]Muller AP, Fernandez AM, Haas C, Zimmer E, Portela LV, Torres-Aleman I: Reduced brain insulin-like growth factor I function during aging. Mol Cell Neurosci 2012, 49(1):9-12.
• [349]Gong X, Ma M, Fan X, Li M, Liu Q, Liu X, Xu G: Down-regulation of IGF-1/IGF-1R in hippocampus of rats with vascular dementia. Neurosci Lett 2012, 513(1):20-24.
• [350]Zhao J, Harada N, Kurihara H, Nakagata N, Okajima K: Cilostazol improves cognitive function in mice by increasing the production of insulin-like growth factor-I in the hippocampus. Neuropharmacology 2010, 58(4–5):774-783.
• [351]Carmeli E, Coleman R, Reznick AZ: The biochemistry of aging muscle. Exp Gerontol 2002, 37(4):477-489.
• [352]Le Roith D, Bondy C, Yakar S, Liu JL, Butler A: The somatomedin hypothesis: 2001. Endocr Rev 2001, 22(1):53-74.
• [353]Florini JR, Ewton DZ, Coolican SA: Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 1996, 17(5):481-517.
• [354]Dennis RA, Przybyla B, Gurley C, Kortebein PM, Simpson P, Sullivan DH, Peterson CA: Aging alters gene expression of growth and remodeling factors in human skeletal muscle both at rest and in response to acute resistance exercise. Physiol Genomics 2008, 32(3):393-400.
• [355]Li M, Li C, Parkhouse WS: Age-related differences in the des IGF-I-mediated activation of Akt-1 and p70 S6K in mouse skeletal muscle. Mech Ageing Dev 2003, 124(7):771-778.
• [356]Berryman DE, Christiansen JS, Johannsson G, Thorner MO, Kopchick JJ: Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. Growth Horm IGF Res 2008, 18(6):455-471.
• [357]Bex M, Bouillon R: Growth hormone and bone health. Horm Res 2003, 60(Suppl 3):80-86.
• [358]Giustina A, Mazziotti G, Canalis E: Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008, 29(5):535-559.
• [359]Sell C, Ptasznik A, Chang CD, Swantek J, Cristofalo VJ, Baserga R: IGF-1 receptor levels and the proliferation of young and senescent human fibroblasts. Biochem Biophys Res Commun 1993, 194(1):259-265.
• [360]Pfeilschifter J, Diel I, Pilz U, Brunotte K, Naumann A, Ziegler R: Mitogenic responsiveness of human bone cells in vitro to hormones and growth factors decreases with age. J Bone Miner Res: the official journal of the American Society for Bone and Mineral Research 1993, 8(6):707-717.
• [361]Hirschberg R, Adler S: Insulin-like growth factor system and the kidney: physiology, pathophysiology, and therapeutic implications. Am J Kidney Dis: the official journal of the National Kidney Foundation 1998, 31(6):901-919.
• [362]Rogers SA, Powell-Braxton L, Hammerman MR: Insulin-like growth factor I regulates renal development in rodents. Dev Genet 1999, 24(3–4):293-298.
• [363]Bridgewater DJ, Ho J, Sauro V, Matsell DG: Insulin-like growth factors inhibit podocyte apoptosis through the PI3 kinase pathway. Kidney Int 2005, 67(4):1308-1314.
• [364]Flyvbjerg A: Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000, 43(10):1205-1223.
• [365]Wang SN, LaPage J, Hirschberg R: Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int 2000, 57(3):1002-1014.
• [366]Kang BP, Urbonas A, Baddoo A, Baskin S, Malhotra A, Meggs LG: IGF-1 inhibits the mitochondrial apoptosis program in mesangial cells exposed to high glucose. Am J Physiol Renal Physiol 2003, 285(5):F1013-F1024.
• [367]Skjaerbaek C, Frystyk J, Orskov H, Kissmeyer-Nielsen P, Jensen MB, Laurberg S, Moller N, Flyvbjerg A: Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: the possible role of insulin-like growth factor-binding protein-3 proteolysis. J Clin Endocrinol Metab 1998, 83(7):2445-2449.
• [368]Lang CH, Fan J, Frost RA, Gelato MC, Sakurai Y, Herndon DN, Wolfe RR: Regulation of the insulin-like growth factor system by insulin in burn patients. J Clin Endocrinol Metab 1996, 81(7):2474-2480.
• [369]Sermet-Gaudelus I, Souberbielle JC, Azhar I, Ruiz JC, Magnine P, Colomb V, Le Bihan C, Folio D, Lenoir G: Insulin-like growth factor I correlates with lean body mass in cystic fibrosis patients. Arch Dis Child 2003, 88(11):956-961.
• [370]Congote LF: Monitoring insulin-like growth factors in HIV infection and AIDS. Clin Chim Acta 2005, 361(1–2):30-53.
• [371]Clemmons DR: Clinical utility of measurements of insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2006, 2(8):436-446.
• [372]Bondy CA, Underwood LE, Clemmons DR, Guler HP, Bach MA, Skarulis M: Clinical uses of insulin-like growth factor I. Ann Intern Med 1994, 120(7):593-601.
• [373]Ketelslegers JM, Maiter D, Maes M, Underwood LE, Thissen JP: Nutritional regulation of insulin-like growth factor-I. Metab Clin Exp 1995, 44(10 Suppl 4):50-57.
• [374]Pascal N, Amouzou EK, Sanni A, Namour F, Abdelmouttaleb I, Vidailhet M, Gueant JL: Serum concentrations of sex hormone binding globulin are elevated in kwashiorkor and anorexia nervosa but not in marasmus. Am J Clin Nutr 2002, 76(1):239-244.
• [375]Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, Koller D, Rosenfeld RG: Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab 2006, 91(5):1826-1831.
• [376]Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE, Group GHISC: Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007, 92(3):902-910.
• [377]Backeljauw PF, Underwood LE: Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome--a clinical research center study. GHIS Collaborative Group. J Clin Endocrinol Metab 1996, 81(9):3312-3317.
• [378]Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Blum WF, Wilton P: Insulin-like growth factor I improves height in growth hormone insensitivity: two years’ results. Horm Res 1995, 44(6):253-264.
• [379]Guevara-Aguirre J, Vasconez O, Martinez V, Martinez AL, Rosenbloom AL, Diamond FB Jr, Gargosky SE, Nonoshita L, Rosenfeld RG: A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 1995, 80(4):1393-1398.
• [380]Laron Z, Anin S, Klipper-Aurbach Y, Klinger B: Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992, 339(8804):1258-1261.
• [381]Laron Z, Klinger B: Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). Eur J Endocrinol 1998, 138(2):176-180.
• [382]Rosenbloom AL: Recombinant human insulin-like growth factor I (rhIGF-I) and rhIGF-I/rhIGF-binding-protein-3: new growth treatment options? J Pediatr 2007, 150(1):7-11.
• [383]Balhara B, Misra M, Levitsky LL: Recombinant human IGF-1 (insulin-like growth factor) therapy: where do we stand today? Indian J Pediatr 2012, 79(2):244-249.
• [384]Rosenbloom AL: Mecasermin (recombinant human insulin-like growth factor I). Adv Ther 2009, 26(1):40-54.
• [385]Ekstrom K, Carlsson-Skwirut C, Ritzen EM, Bang P: Insulin-like growth factor-I and insulin-like growth factor binding protein-3 cotreatment versus insulin-like growth factor-I alone in two brothers with growth hormone insensitivity syndrome: effects on insulin sensitivity, body composition and linear growth. Horm Res Paediatr 2011, 76(5):355-366.
• [386]Laron Z: Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity). Pediatric endocrinology reviews: PER 2008, 5(3):766-771.
• [387]Midyett LK, Rogol AD, Van Meter QL, Frane J, Bright GM, Group MSS: Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial. J Clin Endocrinol Metab 2010, 95(2):611-619.
• [388]Bright GM, Rogers D, Gonzalez-Mendoza LJF: Safety and efficacy of oncedaily rhIGF-1 treatment in prepubertal children with primary IGF-1 deficiency: results from a clinical trial. Rio de Janeiro (Brazil); 2008. [ICE 2008 meeting: 2008]
• [389]Bright GM, Mendoza JR, Rosenfeld RG: Recombinant human insulin-like growth factor-1 treatment: ready for primetime. Endocrinol Metab Clin North Am 2009, 38(3):625-638.
• [390]Frystyk J, Freda P, Clemmons DR: The current status of IGF-I assays–a 2009 update. Growth Horm IGF Res 2010, 20(1):8-18.
• [391]Belobrajdic DP, Priebe IK, Forbes B, Flyvbjerg A, Chen JW, Cosgrove LJ, Frystyk J, Saunders IW: Assessing the potential usefulness of IGF-related peptides and adiponectin for predicting disease risk. Growth Horm IGF Res 2008, 18(3):198-204.
• [392]Brand-Miller JC, Liu V, Petocz P, Baxter RC: The glycemic index of foods influences postprandial insulin-like growth factor-binding protein responses in lean young subjects. Am J Clin Nutr 2005, 82(2):350-354.
• [393]Juul A: Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003, 13(4):113-170.
• [394]Liao S, Guevara-Aguirre J, Bright G: Validation of a population pharmacokinetic (POP-PK) model for rhIGF-1 in humans. San Diego (California); 2005. [ENDO]
• [395]Wilton P: Adverse events reported in KIGS. In Growth hormone therapy in pediatrics: 20 years of KIGS. Edited by Ranke MB, Price DA, Reiter EO. Karger, Basel, Switzerland; 2007:432-441.
• [396]Maneatis T, Baptista J, Connelly K, Blethen S: Growth hormone safety update from the national cooperative growth study. J Pediatr Endocrinol Metab 2000, 13(Suppl 2):1035-1044.
• [397]Klinger B, Laron Z: Three year IGF-I treatment of children with laron syndrome. J Pediatr Endocrinol Metab 1995, 8(3):149-158.
• [398]Ebeling PR, Jones JD, O’Fallon WM, Janes CH, Riggs BL: Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women. J Clin Endocrinol Metab 1993, 77(5):1384-1387.
• [399]Conchillo M, de Knegt RJ, Payeras M, Quiroga J, Sangro B, Herrero JI, Castilla-Cortazar I, Frystyk J, Flyvbjerg A, Yoshizawa C, et al.: Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol 2005, 43(4):630-636.
• [400]Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N: Long-term IGF-I treatment of children with laron syndrome increases adiposity. Growth Horm IGF Res 2006, 16(1):61-64.
• [401]McDonald A, Williams RM, Regan FM, Semple RK, Dunger DB: IGF-I treatment of insulin resistance. Eur J Endocrinol 2007, 157(Suppl 1):S51-S56.
• [402]Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012, 12(3):159-169.
• [403]Steuerman R, Shevah O, Laron Z: Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur J Endocrinol 2011, 164(4):485-489.
• [404]Nakae J, Kato M, Murashita M, Shinohara N, Tajima T, Fujieda K: Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. J Clin Endocrinol Metab 1998, 83(2):542-549.
• [405]de la Monte SM: Insulin resistance and alzheimer’s disease. BMB Rep 2009, 42(8):475-481.
• [406]Lopez-Lopez C, Dietrich MO, Metzger F, Loetscher H, Torres-Aleman I: Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of alzheimer’s disease. J Neurosci 2007, 27(4):824-831.
• [407]Mitchell JD, Wokke JH, Borasio GD: Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2007, (4):CD002064. PMID: 17943766
• [408]Switzer M, Rice J, Rice M, Hardin DS: Insulin-like growth factor-I levels predict weight, height and protein catabolism in children and adolescents with cystic fibrosis. J Pediatr Endocrinol Metab 2009, 22(5):417-424.
• [409]Jacob R, Barrett E, Plewe G, Fagin KD, Sherwin RS: Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. Comparison with insulin. J Clin Invest 1989, 83(5):1717-1723.
• [410]Meyer NA, Barrow RE, Herndon DN: Combined insulin-like growth factor-1 and growth hormone improves weight loss and wound healing in burned rats. J Trauma 1996, 41(6):1008-1012.
• [411]Haugaard SB, Andersen O, Hansen BR, Orskov H, Andersen UB, Madsbad S, Iversen J, Flyvbjerg A: Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic human immunodeficiency virus-infected patients. Metab Clin Exp 2004, 53(12):1565-1573.
• [412]Flynn RS, Murthy KS, Grider JR, Kellum JM, Kuemmerle JF: Endogenous IGF-I and alphaVbeta3 integrin ligands regulate increased smooth muscle hyperplasia in stricturing Crohn’s disease. Gastroenterology 2010, 138(1):285-293.
• [413]Fletcher L, Kohli S, Sprague SM, Scranton RA, Lipton SA, Parra A, Jimenez DF, Digicaylioglu M: Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation. J Neurosurg 2009, 111(1):164-170.
• [414]Murillo-Cuesta S, Rodriguez-de la Rosa L, Cediel R, Lassaletta L, Varela-Nieto I: The role of insulin-like growth factor-I in the physiopathology of hearing. Front Mol Neurosci 2011, 4:11.
• [415]Abdulle AM, Gillett MP, Abouchacra S, Sabri SM, Rukhaimi MA, Obineche EN, Singh J: Low IGF-1 levels are associated with cardiovascular risk factors in haemodialysis patients. Mol Cell Biochem 2007, 302(1–2):195-201.
• [416]Boonen S, Rosen C, Bouillon R, Sommer A, McKay M, Rosen D, Adams S, Broos P, Lenaerts J, Raus J, et al.: Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J Clin Endocrinol Metab 2002, 87(4):1593-1599.
• [417]Rubin CD, Reed B, Sakhaee K, Pak CY: Treating a patient with the Werner syndrome and osteoporosis using recombinant human insulin-like growth factor. Ann Intern Med 1994, 121(9):665-668.
• [418]De Ravin SS, Shum E, Zarember KA, Rezvani G, Rosenfeld RG, Stratakis CA, Malech HL: Short stature in partially corrected X-linked severe combined immunodeficiency–suboptimal response to growth hormone. J Pediatr Endocrinol Metab 2008, 21(11):1057-1063.
• [419]Heatwole CR, Eichinger KJ, Friedman DI, Hilbert JE, Jackson CE, Logigian EL, Martens WB, McDermott MP, Pandya SK, Quinn C, et al.: Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1. Arch Neurol 2011, 68(1):37-44.
• [420]Misra M, McGrane J, Miller KK, Goldstein MA, Ebrahimi S, Weigel T, Klibanski A: Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa. Bone 2009, 45(3):493-498.
• [421]Hollis ER II, Lu P, Blesch A, Tuszynski MH: IGF-I gene delivery promotes corticospinal neuronal survival but not regeneration after adult CNS injury. Exp Neurol 2009, 215(1):53-59.
• [422]Hansen-Pupp I, Engstrom E, Niklasson A, Berg AC, Fellman V, Lofqvist C, Hellstrom A, Ley D: Fresh-frozen plasma as a source of exogenous insulin-like growth factor-I in the extremely preterm infant. J Clin Endocrinol Metab 2009, 94(2):477-482.
• [423]Katz LE, Ferry RJ Jr, Stanley CA, Collett-Solberg PF, Baker L, Cohen P: Suppression of insulin oversecretion by subcutaneous recombinant human insulin-like growth factor I in children with congenital hyperinsulinism due to defective beta-cell sulfonylurea receptor. J Clin Endocrinol Metab 1999, 84(9):3117-3124.
• [424]Diez-Caballero F, Castilla-Cortazar I, Garcia-Fernandez M, Puche JE, Diaz-Sanchez M, Casares AD, Aliaga-Montilla MA, Rodriguez-Borrajo C, Gonzalez-Baron S: Little effects of insulin-like growth factor-I on testicular atrophy induced by hypoxia. BMC Urol 2006, 6:4. BioMed Central Full Text
• [425]Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, et al.: Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999, 5(12):1390-1395.